Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Blood (2023) 141 (7): 743–755.

https://doi.org/10.1182/blood.2022016975

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

Journal Articles

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy

Wilhelm Woessmann, Martin Zimmermann, Andrea Meinhardt, Stephanie Müller, Holger Hauch, Fabian Knörr, Ilske Oschlies, Wolfram Klapper, Felix Niggli, Edita Kabickova, Andishe Attarbaschi, Alfred Reiter, Birgit Burkhardt

Blood (2020) 135 (14): 1124–1132.

https://doi.org/10.1182/blood.2019003591

Published: 2020

Includes: Supplemental data

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R. Bartram, PhD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, Rita Beier, MD, Gunnar Cario, Franco Locatelli, MD, Giuseppe Basso, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter

Blood (2016) 128 (22): 4.

https://doi.org/10.1182/blood.V128.22.4.4

Published: 2016

Journal Articles

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Blood (2016) 127 (17): 2101–2112.

https://doi.org/10.1182/blood-2015-09-670729

Published: 2016

Includes: Supplemental data

Journal Articles

Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report

Wilhelm Woessmann, MD, Martin Zimmermann, Birgit Burkhardt, Andrea Meinhardt, MD, Christine Rosenbusch, MD, Vera Vaillant, MD, Ilske Oschlies, Wolfram Klapper, MD, Felix Niggli, MD, Andishe Attarbaschi, MD, Georg Mann, MD, Martin Schrappe, MD, Alfred Reiter, MD

Blood (2014) 124 (21): 1738.

https://doi.org/10.1182/blood.V124.21.1738.1738

Published: 2014

Journal Articles

Invasive Fungal Infections in Pediatric Acute Lymphoblastic Leukemia: Incidence, Characterization, Outcome and Risk Analysis of Study ALL-BFM 2000

Georg Mann, MD, Andishe Attarbaschi, MD PhD, Martin Schrappe, MD, Anja Möricke, Kirsten Bleckmann, MD, Julia Alten, MD, Thomas Lehrnbecher, MD, Martin Zimmermann, PhD, Felix Niggli, MD

Blood (2014) 124 (21): 3658.

https://doi.org/10.1182/blood.V124.21.3658.3658

Published: 2014

Journal Articles

Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence

Bettina R. Bonn, Marius Rohde, Martin Zimmermann, David Krieger, Ilske Oschlies, Felix Niggli, Grazyna Wrobel, Andishe Attarbaschi, Gabriele Escherich, Wolfram Klapper, Alfred Reiter, Birgit Burkhardt

Blood (2013) 121 (16): 3153–3160.

https://doi.org/10.1182/blood-2012-12-474148

Published: 2013

Includes: Supplemental data

Journal Articles

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Anja Möricke, MD, André Schrauder, MD, Martin Zimmermann, PhD, Georg Mann, MD, Andishe Attarbaschi, MD, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Martin Stanulla, MD, MSc, Gunnar Cario, MD, Alfred Reiter, MD, Felix Niggli, MD, Claus R Bartram, MD, Martin Schrappe, MD

Blood (2011) 118 (21): 1504.

https://doi.org/10.1182/blood.V118.21.1504.1504

Published: 2011

Journal Articles

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Blood (2010) 115 (16): 3206–3214.

https://doi.org/10.1182/blood-2009-10-248146

Published: 2010

Includes: Supplemental data

Journal Articles

Non-Hodgkin Lymphoma in Adolescents: Experiences in 378 Adolescent NHL Patients Treated According to Pediatric NHL-BFM Protocols.

Birgit Burkhardt, MD, PhD, Ilske Oschlies, MD, Wolfram Klapper, MD, PhD, Martin Zimmermann, PhD, Andrea Meinhardt, MD, Eva Landmann, MD, Wilhelm Woessmann, MD, PhD, Georg Mann, MD, Felix Niggli, MD, Martin Schrappe, MD, PhD, Alfred Reiter, MD, PhD

Blood (2009) 114 (22): 102.

https://doi.org/10.1182/blood.V114.22.102.102

Published: 2009

Journal Articles

Leukemia-Initiating Cells Are Frequent in Very High Risk Childhood Acute Lymphoblastic Leukemia and Give Rise to Relatively Stable Phenotypes in Immunodeficient Mice.

Maike Schmitz, MSc, Paulina Mirkowska, MSc, Petra Breithaupt, PhD, Barbara Meissner, MD, Gunnar Cario, MD, Andre Schrauder, MD, Felix Niggli, MD, Martin Schrappe, MD, Martin Stanulla, MD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD, PhD

Blood (2009) 114 (22): 86.

https://doi.org/10.1182/blood.V114.22.86.86

Published: 2009

Journal Articles

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R Bartram, MD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, André Schrauder, MD, Franco Locatelli, MD, Alfred Reiter, MD, Giuseppe Basso, MD, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter, MD

Blood (2008) 112 (11): 7.

https://doi.org/10.1182/blood.V112.11.7.7

Published: 2008

Journal Articles

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Blood (2008) 111 (9): 4477–4489.

https://doi.org/10.1182/blood-2007-09-112920

Published: 2008

Includes: Supplemental data

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

Journal Articles

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

Anja Möricke, MD, Alfred Reiter, MD, Martin Zimmermann, PhD, Helmut Gadner, MD, Martin Stanulla, MD, Wolf-Dieter Ludwig, MD, Jochen Harbott, PhD, Georg Mann, MD, Felix Niggli, MD, Günter Henze, MD, Karl Welte, MD, Thomas Klingebiel, MD, Charlotte Niemeyer, MD, Felix Zintl, MD, Hansjörg Riehm, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 584.

https://doi.org/10.1182/blood.V110.11.584.584

Published: 2007

Journal Articles

The BH3-Mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy.

Laura Bonapace, Beat C. Bornhauser, PhD, Gunnar Cario, MD, Martin Schrappe, MD, Felix Niggli, MD, Beat W. Schaefer, PhD, Jean-Pierre Bourquin, MD, PhD

Blood (2007) 110 (11): 806.

https://doi.org/10.1182/blood.V110.11.806.806

Published: 2007

Journal Articles

CNS Involvement in Childhood and Adolescence Non-Hodgkin Lymphoma: Prevalence and Patient’s Outcome Differ According to the Subtype.

Janina Salzburg, MD, Birgit Burkhardt, MD, Olga Wachowski, MD, Martin Zimmermann, PhD, Reza Parwaresch, MD, Wolf-Dieter Ludwig, MD, Georg Mann, MD, Felix Niggli, MD, Hansjörg Riehm, MD, Martin Schrappe, MD, Alfred Reiter, MD

Blood (2005) 106 (11): 233.

https://doi.org/10.1182/blood.V106.11.233.233

Published: 2005

NARROW

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report

Invasive Fungal Infections in Pediatric Acute Lymphoblastic Leukemia: Incidence, Characterization, Outcome and Risk Analysis of Study ALL-BFM 2000

Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Non-Hodgkin Lymphoma in Adolescents: Experiences in 378 Adolescent NHL Patients Treated According to Pediatric NHL-BFM Protocols.

Leukemia-Initiating Cells Are Frequent in Very High Risk Childhood Acute Lymphoblastic Leukemia and Give Rise to Relatively Stable Phenotypes in Immunodeficient Mice.

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

The BH3-Mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy.

CNS Involvement in Childhood and Adolescence Non-Hodgkin Lymphoma: Prevalence and Patient’s Outcome Differ According to the Subtype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only